Colorectal Cancer Immunotherapy: Options and Strategies

被引:340
作者
Johdi, Nor Adzimah [1 ]
Sukor, Nur Fazilah [1 ]
机构
[1] Natl Univ Malaysia, UKM Med Mol Biol Inst UMBI, Bangi, Malaysia
关键词
colorectal carcinoma; immunotherapy; FDA; T-cells; antibodies; cytokines; treatments; CHIMERIC ANTIGEN RECEPTOR; PHASE-I TRIAL; TUMOR-INFILTRATING LYMPHOCYTES; PROSTATIC ACID-PHOSPHATASE; ESMO CONSENSUS GUIDELINES; MOLONEY LEUKEMIA-CELLS; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; CEA MESSENGER-RNA; RANDOMIZED-TRIAL;
D O I
10.3389/fimmu.2020.01624
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients' own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients' own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life.
引用
收藏
页数:18
相关论文
共 215 条
[1]  
ABBASI AM, 1992, J PATHOL, V168, P405
[2]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[3]  
Alatrash G, 2019, TUMOR ASS ANTIGENS I, P107, DOI [10.1016/B978-0-12-812630-1.00007-4, DOI 10.1016/B978-0-12-812630-1.00007-4]
[4]   T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].
Ali, Syed Abbas ;
Shi, Victoria ;
Maric, Irina ;
Wang, Michael ;
Stroncek, David F. ;
Rose, Jeremy J. ;
Brudno, Jennifer N. ;
Stetler-Stevenson, Maryalice ;
Feldman, Steven A. ;
Hansen, Brenna G. ;
Fellowes, Vicki S. ;
Hakim, Frances T. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
BLOOD, 2016, 128 (13) :1688-1700
[5]   Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].
Andtbacka, Robert H. I. ;
Kaufman, Howard L. ;
Collichio, Frances ;
Amatruda, Thomas ;
Senzer, Neil ;
Chesney, Jason ;
Delman, Keith A. ;
Spitler, Lynn E. ;
Puzanov, Igor ;
Agarwala, Sanjiv S. ;
Milhem, Mohammed ;
Cranmer, Lee ;
Curti, Brendan ;
Lewis, Karl ;
Ross, Merrick ;
Guthrie, Troy ;
Linette, Gerald P. ;
Daniels, Gregory A. ;
Harrington, Kevin ;
Middleton, Mark R. ;
Miller, Wilson H., Jr. ;
Zager, Jonathan S. ;
Ye, Yining ;
Yao, Bin ;
Li, Ai ;
Doleman, Susan ;
VanderWalde, Ari ;
Gansert, Jennifer ;
Coffin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98
[6]  
[Anonymous], 2019, MOLECULES
[7]  
[Anonymous], 2018, J IMMUNOTHER CANCER
[8]   Global patterns and trends in colorectal cancer incidence and mortality [J].
Arnold, Melina ;
Sierra, Monica S. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
GUT, 2017, 66 (04) :683-691
[9]  
BARRETO L, 1992, DEV BIOLOGICALS, V77, P229
[10]   Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street [J].
Barrett, David M. ;
Grupp, Stephan A. ;
June, Carl H. .
JOURNAL OF IMMUNOLOGY, 2015, 195 (03) :755-761